靶向剪切力敏感关键分子的动脉粥样硬化防治研究

doi:10.16352/j.issn.1001-6325.2022.03.031

摘要/Abstract

摘要： 临床与基础医学证据表明,流体剪切力与粥样硬化等动脉病理改变密切相关。在大动脉弯曲或分叉处的血流扰动,可对内皮细胞产生较低且不规则的剪切力,诱导内皮功能障碍和损伤,促进动脉粥样硬化的发生。而在大动脉长、直段的层流所产生的高且规则的剪切力,则保护血管内皮且抑制动脉粥样硬化发生。本文重点关注在动脉粥样硬化的发生发展中,受到剪切力调控并且对疾病引发有关键作用的转录因子或辅助因子,并概述以其为靶点的动脉粥样硬化相关血管病变的防治策略研究。

关键词: 流体剪切力, 剪切力敏感分子, 动脉粥样硬化, 药物筛选, 转录因子

Abstract: Clinical and basic research evidence suggests a critical role of local hemodynamic microenvironments in atherogenesis. Disturbed flow with a low and reciprocating shear stress in arterial branches and curvatures induces endothelial dysregulation and damage, leading to atherosclerosis. In contrast, laminar flow with a high and unidirectional shear stress in the straight parts of the arteries elicits an atheroprotective effect on the vasculature. Effective treatment against endothelial dysregulation and the consequent atherogenesis requires the identification of new shear-responsive molecules and the development of drugs targeting these molecules. In this review, we focus on the role of shear-responsive transcription factors and cofactors in endothelial dysfunction and atherosclerosis, and highlight future direction for prevention and treatment of atherosclerosis by targeting these factors.

Key words: hemodynamic shear stress, shear-responsive factor, atherosclerosis, drug screening, transcription factor

中图分类号:

R310.21

赵川榕, 周菁. 靶向剪切力敏感关键分子的动脉粥样硬化防治研究[J]. 基础医学与临床, 2022, 42(3): 378-383.

ZHAO Chuan-rong, ZHOU Jing. Shear-sensitive factors in therapeutic targets for atherosclerosis[J]. Basic & Clinical Medicine, 2022, 42(3): 378-383.

参考文献

[1]CHIU JJ, CHIEN S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives[J]. Physiol Rev, 2011, 91: 327-387.
[2]ZHOU J, LI YS, CHIEN S. Shear stress-initiated signaling and its regulation of endothelial function[J]. Arterioscler Thromb Vasc Biol, 2014, 34: 2191-2198.
[3]XU S. Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis[J]. Pharmacol Res, 2020, 155: 104737.
[4]LE NT, HEO KS, TAKEI Y, et al. A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis[J]. Circulation, 2013, 127: 486-499.
[5]ZHOU G, HAMIK A, NAYAK L, et al. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice[J]. J Clin Invest, 2012, 122: 4727-4731.
[6]NIU N, XU S, XU Y, et al. Targeting mechanosensitive transcription factors in atherosclerosis[J]. Trends Pharmacol Sci, 2019, 40: 253-266.
[7]READ MA, WHITLEY MZ, WILLIAMS AJ, et al. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation[J]. J Exp Med, 1994, 179: 503-512.
[8]PAMUKCU B, LIP GY, SHANTSILA E. The nuclear factor--kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease[J]. Thromb Res, 2011, 128: 117-123.
[9]SANTIAGO FS, LI Y, ZHONG L, et al. Truncated YY1 interacts with BASP1 through a 339KLK341 motif in YY1 and suppresses vascular smooth muscle cell growth and intimal hyperplasia after vascular injury[J]. Cardiovasc Res, 2021, 117: 2395-2406.
[10]BECK K, WU BJ, NI J, et al. Interplay between heme oxygenase-1 and the multifunctional transcription factor yin yang 1 in the inhibition of intimal hyperplasia[J]. Circ Res, 2010, 107: 1490-1497.
[11]WEI SY, SHIH YT, WU HY, et al. Endothelial Yin Yang 1 phosphorylation at S118 induces atherosclerosis under flow[J]. Circ Res, 2021,29:1158-1174.
[12]SARVAGALLA S, KOLAPALLI SP, VALLABHAPURAPU S. The two sides of YY1 in cancer: afriend and a foe[J]. Front Oncol, 2019, 9: 1230.doi: 10.3389/fonc.2019.01230
[13]QIN W, YANG H, LIU G, et al. Activating transcription factor 3 is a potential target and a new biomarker for the prognosis of atherosclerosis[J]. Hum Cell, 2021, 34: 49-59.
[14]THOMPSON MR, XU D, WILLIAMS BR. ATF3 transcription factor and its emerging roles in immunity and cancer[J]. J Mol Med (Berl), 2009, 87: 1053-1060.
[15]TEASDALE JE, HAZELL GG, PEACHEY AM, et al. Cigarette smoke extract profoundly suppresses TNFalpha-mediated proinflammatory gene expression through upregulation of ATF3 in human coronary artery endothelial cells[J]. Sci Rep, 2017, 7: 39945.doi: 10.1038/srep39945.
[16]PENG J, LE CY, XIA B, et al. Research on the correlation between activating transcription factor 3 expression in the human coronary artery and atherosclerotic plaque stability[J]. BMC Cardiovasc Disord, 2021, 21: 356.doi: 10.1186/s12872-021-02161-9.
[17]FELIZOLA SJ, NAKAMURA Y, OZAWA Y, et al. Activat-ing transcription factor 3 (ATF3) in the human adrenal cortex: its possible involvement in aldosterone biosynthesis[J]. Tohoku J Exp Med, 2014, 234: 249-254.
[18]CAI Y, ZHANG C, NAWA T, et al. Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element[J]. Blood, 2000, 96: 2140-2148.
[19]KAWAUCHI J, ZHANG C, NOBORI K, et al. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription[J]. J Biol Chem, 2002, 277: 39025-39034.
[20]WANG CM, BRENNAN VC, GUTIERREZ NM, et al. SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene[J]. J Cell Biochem, 2013, 114: 589-598.
[21]MIN E, SCHWARTZ MA. Translocating transcription factors in fluid shear stress-mediated vascular remodeling and disease[J]. Exp Cell Res, 2019, 376: 92-97.
[22]XU S, KOROLEVA M, YIN M, et al. Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells[J]. Transl Res, 2016, 176: 18-28 e2.
[23]WANG L, LUO JY, LI B, et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow[J]. Nature, 2016, 540: 579-582.
[24]WANG KC, YEH YT, NGUYEN P, et al. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis[J]. Proc Natl Acad Sci U S A, 2016, 113: 11525-11530.
[25]LIU-CHITTENDEN Y, HUANG B, SHIM JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP[J]. Genes Dev, 2012, 26: 1300-1305.
[26]WU P, LIU Z, ZHAO T, et al. Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling[J]. Biochem Biophys Res Commun, 2019, 512: 736-741.
[27]WAN L, ZHANG Q, WANG S, et al. Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis[J]. Phytother Res, 2019, 33: 1579-1591.
[28]LIU D, LV H, LIU Q, et al. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under distur-bed flow[J]. J Transl Med, 2019, 17: 378.doi: 10.1186/s12967-019-02135-8
[29]MACDONALD BT, TAMAI K, HE X. Wnt/beta-catenin signaling: components, mechanisms, and diseases[J]. Dev Cell, 2009, 17: 9-26.
[30]GOODWIN AM, D'AMORE PA. Wnt signaling in the vasculature[J]. Angiogenesis, 2002, 5: 1-9.
[31]REIS M, LIEBNER S. Wnt signaling in the vasculature[J]. Exp Cell Res, 2013, 319: 1317-1323.
[32]LI R, BEEBE T, JEN N, et al. Shear stress-activated Wnt-angiopoietin-2 signaling recapitulates vascular repair in zebrafish embryos[J]. Arterioscler Thromb Vasc Biol, 2014, 34: 2268-2275.
[33]GELFAND BD, MELLER J, PRYOR AW, et al. Hemodynamic activation of beta-catenin and T-cell-specific transcription factor signaling in vascular endothelium regulates fibronectin expression[J]. Arterioscler Thromb Vasc Biol, 2011, 31: 1625-1633.
[34]BASTAKOTY D, SARASWATI S, JOSHI P, et al. Temporary, systemic inhibition of the WNT/beta-catenin pathway promotes regenerative cardiac repair following myocardial infarct[J]. Cell Stem Cells Regen Med, 2016, 2.doi: 10.16966/2472-6990.111
[35]CHEN L, ZHUANG J, SINGH S, et al. XAV939 inhibits intima formation by decreasing vascular smooth muscle cell proliferation and migration through blocking Wnt signaling[J]. J Cardiovasc Pharmacol, 2016, 68: 414-424.
[36]LI M, WILSON DM, 3rd. Human apurinic/apyrimidinic endonuclease 1[J]. Antioxid Redox Signal, 2014, 20: 678-707.
[37]PARK MS, KIM CS, JOO HK, et al. Cytoplasmic localization and redox cysteine residue of APE1/Ref-1 are associated with its anti-inflammatory activity in cultured endothelial cells[J]. Mol Cells, 2013, 36: 439-445.
[38]ZHAO CR, YANG FF, CUI Q, et al. Vitexin inhibits APEX1 to counteract the flow-induced endothelial inflammation[J]. Proc Natl Acad Sci U S A, 2021, 118: e2115158118.doi: 10.1073/pnas.2115158118.
[39]LEE IW, YOON J, LEE G, et al. Identification of new potential APE1 inhibitors by pharmacophore modeling and molecular docking[J]. Genomics Inform, 2017, 15: 147-155.
[40]LAEV SS, SALAKHUTDINOV NF, LAVRIK OI. Inhibi-tors of nuclease and redox activity of apurinic/apyrimi-dinic endonuclease 1/redox effector factor 1 (APE1/Ref-1)[J]. Bioorg Med Chem, 2017, 25: 2531-2544.
[41]LUO M, DELAPLANE S, JIANG A, et al. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1[J]. Antioxid Redox Signal, 2008, 10: 1853-1867.
[42]MARTINEZ MOLINA D, JAFARI R, IGNATUSHCHENKO M, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay[J]. Science, 2013, 341: 84-87.
[43]NAKAJIMA H, MOCHIZUKI N. Flow pattern-dependent endothelial cell responses through transcriptional regula-tion[J]. Cell Cycle, 2017, 16: 1893-1901.